1. Home
  2. CTKB vs EOLS Comparison

CTKB vs EOLS Comparison

Compare CTKB & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • EOLS
  • Stock Information
  • Founded
  • CTKB 1990
  • EOLS 2012
  • Country
  • CTKB United States
  • EOLS United States
  • Employees
  • CTKB N/A
  • EOLS N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • EOLS Health Care
  • Exchange
  • CTKB Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • CTKB 718.8M
  • EOLS 702.2M
  • IPO Year
  • CTKB 2021
  • EOLS 2018
  • Fundamental
  • Price
  • CTKB $5.12
  • EOLS $13.99
  • Analyst Decision
  • CTKB Strong Buy
  • EOLS Strong Buy
  • Analyst Count
  • CTKB 2
  • EOLS 6
  • Target Price
  • CTKB $9.25
  • EOLS $23.80
  • AVG Volume (30 Days)
  • CTKB 747.0K
  • EOLS 802.6K
  • Earning Date
  • CTKB 02-27-2025
  • EOLS 03-04-2025
  • Dividend Yield
  • CTKB N/A
  • EOLS N/A
  • EPS Growth
  • CTKB N/A
  • EOLS N/A
  • EPS
  • CTKB N/A
  • EOLS N/A
  • Revenue
  • CTKB $201,210,000.00
  • EOLS $248,326,000.00
  • Revenue This Year
  • CTKB $7.26
  • EOLS $34.38
  • Revenue Next Year
  • CTKB $8.20
  • EOLS $31.94
  • P/E Ratio
  • CTKB N/A
  • EOLS N/A
  • Revenue Growth
  • CTKB 9.88
  • EOLS 34.42
  • 52 Week Low
  • CTKB $4.66
  • EOLS $9.25
  • 52 Week High
  • CTKB $9.33
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 37.48
  • EOLS 54.04
  • Support Level
  • CTKB $5.18
  • EOLS $14.50
  • Resistance Level
  • CTKB $5.48
  • EOLS $15.06
  • Average True Range (ATR)
  • CTKB 0.27
  • EOLS 0.86
  • MACD
  • CTKB 0.01
  • EOLS -0.00
  • Stochastic Oscillator
  • CTKB 27.85
  • EOLS 27.38

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: